Insomnia Market Witnesses Robust Growth During the Forecast Period (2026-2036) with Emerging Orexin Receptor Antagonists and Melatonin Receptor Agonist | DelveInsight
The insomnia market is expected to increase throughout the study period due to several factors. Increased awareness of the disease has led to more cases being treated, contributing to market growth. Additionally, the rising number of clinical trials of therapies including Seltorexant (JNJ-42847922) (Johnson & Johnson), HETLIOZ (tasimelteon) (Vanda Pharmaceuticals), Daridorexant (Idorsia), SM-1 (EUSOL Biotech), and others is a significant driver of the market's expansion.
LAS VEGAS, June 18, 2026 /PRNewswire/ -- Recently published Insomnia Market Insights report includes a comprehensive understanding of current treatment practices, insomnia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Insomnia Market Summary
Discover which insomnia drug class will dominate the market @ https://www.delveinsight.com/report-store/insomnia-market
Key Factors Driving the Growth of the Insomnia Market
Ramandeep Singh, senior consultant of forecasting at DelveInsight, said that the insomnia market is entering a transformative phase, driven by rising awareness of sleep health, increasing stress-related disorders, and the growing demand for safer, non-habit-forming therapies. Novel orexin receptor antagonists and digital therapeutics are reshaping the competitive landscape.
Insomnia Market Analysis
Insomnia Competitive Landscape
Some of the insomnia drugs under development include Seltorexant (JNJ-42847922) (Johnson & Johnson), HETLIOZ (tasimelteon) (Vanda Pharmaceuticals), Daridorexant (Idorsia), SM-1 (EUSOL Biotech), and others.
Janssen Pharmaceutical's seltorexant (JNJ-42847922) is a selective orexin-2 receptor antagonist being investigated as an adjunctive treatment for major depressive disorder (MDD) as well as for insomnia disorder.
Vanda Pharmaceuticals' HETLIOZ (tasimelteon), also referred to as VEC-162, is a melatonin receptor agonist that targets the human MT1 and MT2 receptors, showing higher affinity for MT2. Acting as a circadian rhythm regulator, the therapy helps reset the body's internal clock through its action on the suprachiasmatic nucleus (SCN) in the hypothalamus.
The anticipated launch of these emerging therapies are poised to transform the insomnia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the insomnia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which companies are leading the insomnia pipeline @ Insomnia Drugs
Recent Developments in the Insomnia Market
What is Insomnia?
Insomnia is a common sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early and being unable to return to sleep. It can be short-term, often triggered by stress, lifestyle changes, or illness, or chronic, lasting for months or longer. People with insomnia frequently experience daytime fatigue, poor concentration, mood disturbances, and reduced productivity, which can significantly affect overall quality of life. The condition may be associated with mental health disorders, neurological conditions, chronic pain, or certain medications, making it an important public health concern worldwide.
Insomnia Epidemiology Segmentation
The insomnia epidemiology section provides insights into the historical and current insomnia patient pool and forecasted trends for the leading markets. According to DelveInsight, the total diagnosed prevalent cases of insomnia in the US comprised approximately 60 million in 2025 and are projected to increase during the forecast period.
The insomnia treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Insomnia Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Insomnia Epidemiology Segmentation
Total Diagnosed Prevalent Cases of Insomnia, Type-specific Diagnosed Prevalent Cases of Insomnia, Gender-specific Diagnosed Prevalent Cases of Insomnia, and Age-specific Diagnosed Prevalent Cases of Insomnia
Key Insomnia Companies
Johnson & Johnson, Vanda Pharmaceuticals, Idorsia, EUSOL Biotech, Cosette Pharmaceuticals, Sanofi, Pfizer, Mallinckrodt Pharmaceuticals, Arovella Therapeutics, Currax Pharmaceuticals, Takeda, Eisai, Idorsia Pharmaceutical, Syneos Health, Mochida Pharmaceutical, Merck, Neurim Pharmaceuticals, Taisho Pharmaceutical, and others
Key Insomnia Therapies
Seltorexant (JNJ-42847922), HETLIOZ (tasimelteon), Daridorexant, SM-1, AMBIEN, SONATA, HALCION, RESTORIL, ZOLPIMIST, SILENOR, ROZEREM, DAYVIGO, QUVIVIQ, BELSOMRA, CIRCADIN, VORZZZ, and others
Scope of the Insomnia Market Report
Download the report to understand how fast is the insomnia therapeutics market growing @ Insomnia Market Analysis
Table of Contents
1
Insomnia Market Key Insights
2
Insomnia Market Report Introduction
3
Insomnia Market Overview at a Glance
3.1
Market Share (%) Distribution of Insomnia by Therapies in the 7MM in 2025
3.2
Market Share (%) Distribution of Insomnia by Therapies in the 7MM in 2036
4
Methodology
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Signs and symptoms
7.3
Causes
7.4
Risk Factors
7.5
Classification
7.6
Diagnostic Approach for Insomnia
7.7
Treatment for Insomnia
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: 7MM
8.3
Total Diagnosed Prevalent Cases of Insomnia in the 7MM
8.4
The United States
8.4.1
Total Diagnosed Prevalent Cases of Insomnia in the US
8.4.2
Type-specific Diagnosed Prevalent Cases of Insomnia in the US
8.4.3
Gender-specific Diagnosed Prevalent Cases of Insomnia in the US
8.4.4
Age-specific Diagnosed Prevalent Cases of Insomnia in the US
8.5
EU4 and the UK
8.6
Japan
9
Patient Journey
10
Marketed Insomnia Drugs
10.1
Key Cross Competition
10.2
DAYVIGO (lemborexant): Eisai
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Clinical Development
10.2.5
Safety and Efficacy
10.2.6
Analyst Views
10.3
QUVIVIQ (daridorexant): Idorsia Pharmaceutical/Mochida Pharmaceutical
List to be continued in the report…
11
Emerging Insomnia Drugs
11.1
Key Cross Competition
11.2
Seltorexant (JNJ-42847922): Johnson & Johnson
11.2.1
Product description
11.2.2
Other development activities
11.2.3
Clinical trials information
11.2.4
Safety and efficacy
11.2.5
Analyst Views
11.3
HETLIOZ (tasimelteon): Vanda Pharmaceuticals
List to be continued in the report…
12
Insomnia: Market Analysis
12.1
Key Findings
12.2
Key Insomnia Market Forecast Assumptions
12.3
Insomnia Market Outlook
12.4
Attribute Analysis
12.5
Total Market Size of Insomnia in the 7MM
12.6
Total Market Size of Insomnia by Therapies in the 7MM
12.7
Market Size of Insomnia in the US
12.7.1
Total Market Size of Insomnia
12.7.2
The Market Size of Insomnia by Therapies
12.8
Market Size of Insomnia in EU4 and the UK
12.9
Market Size of Insomnia in Japan
13
Key Opinion Leaders' Views
14
Unmet Needs
15
SWOT Analysis
16
Market Access and Reimbursement
16.1
The US
16.2
In EU4 and the UK
16.3
Japan
17
Bibliography
18
Acronyms and Abbreviations
19
Insomnia Market Report Methodology
Related Reports
Insomnia Clinical Trial Analysis
Insomnia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key insomnia companies, including Johnson & Johnson, Vanda Pharmaceuticals, Idorsia, EUSOL Biotech, Cosette Pharmaceuticals, Sanofi, Pfizer, Mallinckrodt Pharmaceuticals, Arovella Therapeutics, Currax Pharmaceuticals, Takeda, Eisai, Idorsia Pharmaceutical, Syneos Health, Mochida Pharmaceutical, Merck, Neurim Pharmaceuticals, Taisho Pharmaceutical, and others.
Chronic Insomnia Market
Chronic Insomnia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic insomnia companies, including Eisai Inc., Merck & Co., Idorsia Pharmaceuticals, Janssen Research & Development, Minerva Neurosciences, Sequential Medicine Ltd., and others.
Obstructive Sleep Apnea Market
Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obstructive sleep apnea companies, including Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc., Apnex Medical Inc., and others.
Narcolepsy Market
Narcolepsy Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key narcolepsy companies, including Jazz Pharmaceuticals, Harmony Biosciences, Takeda, Centessa Pharmaceuticals, Alkermes, Axsome Therapeutics, Avadel Pharmaceuticals, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP